Table 2 Case reports of dupilumab administration for non-esophageal eosinophilic gastrointestinal disorders
Case | Age | Sex | Allergic Comorbidities | Endoscopic findings | Eosinophil counts (/µl) | Total IgE (IU/ml) | Previous therapy | Clinical course during the dupilumab treatment | References |
|---|---|---|---|---|---|---|---|---|---|
1 | 7 | M | AD (Severe), FA | Esophagitis, Duodenal ulcer, Colitis | 2010 | 1801 | Food elimination, PPI, Budesonide, Prednisolone | Improvement of endoscopic and pathological findings after 6Â weeks | [27] |
2 | 14 | M | BA (Severe) | Esophagitis, Esophageal stenosis, Jejunal ulcer | 1890 | ND | PPI, Budesonide | Improvement of endoscopic and pathological findings after 4Â months | [27] |
3 | 9 | M | AD (Severe) | Esophagitis, Gastroenteritis, Colitis | ND | ND | Food elimination, PPI, Budesonide/fluticasone, Prednisolone | Improvement of abdominal symptoms and endoscopic findings Discontinuation of budesonide/fluticasone | [27] |
4 | 15 | F | BA (Severe) | Gastroenteritis, Duodenitis Colitis | ND | ND | Milk elimination, Omalizumab, Mepolizumab | Acquisition of milk tolerance | [28] |
5 | 15 | M | AD (Severe) | Duodenal ulcer | 1747 | 2324 | Food elimination, PPI, LTRA, Prednisolone | Improvement of endoscopic and pathological findings after 5Â months Discontinuation of systemic steroid administration | Present case |